GGrantIndex
← Leaderboards

Carl D Novina

Massachusetts Institute Of Technology

$12,702,009
Attributed
$12,702,009
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.2M · FY201122
$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$12,702,009 · 7

By mechanism

R01$7,364,349 · 4
DP1$5,210,000 · 2
F32$127,660 · 1

Top collaborators

No co-investigators on record.

Most similar at Massachusetts Institute Of Technology

Same institution · by research overlap

Others in their field

Top investigators on “Genes

Research focus

GenesBasePathway InteractionsMolecularCellsEctopic ExpressionGeneticProteinsGene TargetingAffectMalignant NeoplasmsKnock-DownTechnologySiteMutationMessenger RnaOncogenesTumorLinkTranscriptome SequencingClinical TrialsTechnology DevelopmentInnovationBiopsy

Grant awards (26)

Defining LncRNA Function in normal and Shwachman Diamond Syndrome Myelopoiesis$441,250
R01 · FY2022 · HL · contact PI
Defining LncRNA Function in normal and Shwachman Diamond Syndrome Myelopoiesis$441,250
R01 · FY2021 · HL · contact PI
Lnc'ing White Fat to Brown Fat Thermogenesis$885,000
DP1 · FY2020 · DK · contact PI
Defining LncRNA Function in normal and Shwachman Diamond Syndrome Myelopoiesis$441,250
R01 · FY2020 · HL · contact PI
Defining LncRNA Function in normal and Shwachman Diamond Syndrome Myelopoiesis$441,250
R01 · FY2019 · HL · contact PI
Engineering epigenetic therapy for sickle cell disease$865,000
DP1 · FY2018 · DK · contact PI
Engineering epigenetic therapy for sickle cell disease$865,000
DP1 · FY2017 · DK · contact PI
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells$613,546
R01 · FY2017 · CA · contact PI
Engineering epigenetic therapy for sickle cell disease$865,000
DP1 · FY2016 · DK · contact PI
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells$696,509
R01 · FY2016 · CA · contact PI
Dysregulated microRNA function in diamond blackfan anemia$347,748
R01 · FY2016 · DK · contact PI
Engineering epigenetic therapy for sickle cell disease$865,000
DP1 · FY2015 · DK · contact PI
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells$692,567
R01 · FY2015 · CA · contact PI
Dysregulated microRNA function in diamond blackfan anemia$347,748
R01 · FY2015 · DK · contact PI
Analysis of cap-dependent translational repression by microRNAs in oncogensis$326,813
R01 · FY2015 · CA · contact PI
Engineering epigenetic therapy for sickle cell disease$865,000
DP1 · FY2014 · DK · contact PI
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells$603,086
R01 · FY2014 · CA · contact PI
Dysregulated microRNA function in diamond blackfan anemia$345,766
R01 · FY2014 · DK · contact PI
Analysis of cap-dependent translational repression by microRNAs in oncogensis$317,009
R01 · FY2014 · CA · contact PI
Dysregulated microRNA function in diamond blackfan anemia$347,727
R01 · FY2013 · DK · contact PI
Analysis of cap-dependent translational repression by microRNAs in oncogensis$307,204
R01 · FY2013 · CA · contact PI
Analysis of cap-dependent translational repression by microRNAs in oncogensis$326,813
R01 · FY2012 · CA · contact PI
Analysis of cap-dependent translational repression by microRNAs in oncogensis$326,813
R01 · FY2011 · CA · contact PI
A B-CELL SPECIFIC COFACTOR OF NUCLEOSOME REMODELING$48,148
F32 · FY2002 · AI
A B-CELL SPECIFIC COFACTOR OF NUCLEOSOME REMODELING$41,996
F32 · FY2001 · AI
A B-CELL SPECIFIC COFACTOR OF NUCLEOSOME REMODELING$37,516
F32 · FY2000 · AI